Alliance Management is Being Neglected

December 2010
Pharmaceutical Representative;Dec2010, Vol. 40 Issue 12, p9
The article reports on the neglect of alliance management in pharmaceutical companies in the U.S.


Related Articles

  • Competitive Pressures for CROs. Henderson, Lisa // Applied Clinical Trials;Nov2010, Vol. 19 Issue 11, p12 

    The article discusses trends in the relationships between pharmaceutical companies and clinical research organizations (CROs) in the U.S. It cites an article published in the June 2009 issue of "Applied Clinical Trials," which found that large and mid-size sponsors to use fewer than five CROs...

  • Pharma at the Crossroads. Sollazzo, Maurizio; Pippitt, Jeanine; Luchino, Paul // Contract Pharma;Mar2012, Vol. 14 Issue 2, p64 

    The article discusses the condition of the pharmaceutical industry in the U.S. which has been challenged by the declining profits, dropping revenues and increasing consumer demand. It highlights the significance of the Laboratory Asset Management Program that has represented as a first step...

  • Stephen Brown, chief operating officer of Encap Drug Delivery.  // Pharmaceutical Technology;Oct2009, Vol. 33 Issue 10, p157 

    An interview with Encap Drug Delivery chief operating officer (CEO) Stephen Brown in the U.S. is presented. He mentions that providing a solution which will make client's overall operations efficient was his biggest industry challenge. He shares that the new trend in pharmaceutical industry will...

  • Sanofi-Aventis Enters Genomic Drug Pact.  // Contract Pharma;Sep2010, Vol. 12 Issue 7, p134 

    The article offers updates on business partnerships related to the U.S. pharmaceutical industry. Scripps Genomic Medicine (SGM) and Sanofi-Aventis have made an alliance with the aim to advance development of personalized medicine. Roche Pharmaceuticals Co. and Aileron Therapeutics Inc. agreed...

  • Industry Briefs.  // CenterWatch Weekly;9/21/2015, Vol. 19 Issue 37, p2 

    The article offers news briefs related to the U.S. pharmaceutical sector that including Certara and Paidion Research partnering to promote drug development for pediatric patients, PRA Health Sciences expanding its presence in Pennsylvania and CureVac launching its U.S. operations.

  • Leveraging Ex-U.S. Deals. Chapin, Matthew; Tobaru, Aki; Van Sandwick // Review of Ophthalmology;Oct2014, Vol. 21 Issue 10, p6 

    The article discusses the value of regional strategic partnerships and licensing as a critical component of new ventures in ophthalmology including defining a target product profile, considerations around raising money, and building an intellectual property. Topics discussed include research and...

  • FSP Relationships: i3 Statprobe and Eli Lilly. Henderson, Lisa // Applied Clinical Trials;Mar2011 Partnerships Supplement, p15 

    The article focuses on the functional services provider (FSP) partnership between pharmaceutical services company i3 Statprobe and pharmaceutical company Eli Lilly & Co. in the U.S. It notes that the partnership of the two companies is a manifestation of how clinical research organizations...

  • Partnering for Success�Survival. Agres, Ted // Drug Discovery & Development;Nov2011, Vol. 14 Issue 11, p12 

    The article reports on the partnership and collaborative agreements between the pharmaceutical and biotechnology industries in the U.S. The author mentions that for pharmaceutical company Big Pharma, such strategy means acquiring more rights to products for commercialization, while reducing...

  • Competitive Landscape.  // U.S. Pharma & Healthcare Report;Q2 2010, p58 

    This article looks at the competitive landscape in the U.S. pharmaceutical industry. It is estimated that the biopharmaceutical sector contributes to three percent of the country's gross domestic product. Pfizer is the biggest pharmaceutical firm operating in the country in terms of value. Other...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics